What is emphysema? Emphysema’s a type of chronic obstructive pulmonary disease (COPD) where the connective tissue in the lungs breaks down, obstructing the airways. Find our full video library only on Osmosis: http://osms.it/more.

Join millions of current and future clinicians who learn by Osmosis, along with hundreds of universities around the world who partner with Osmosis from Elseiver to make medical and health education more engaging and efficient. We have unparalleled tools and materials to prepare you for success in school, on your board exams, and as a future clinician. Sign up for a free trial at http://osms.it/more. If you’re interested in exploring an institutional partnership, visit osmosis.org/educators to request a personalized demo.

Follow us on social:
Facebook: http://osms.it/facebook
Twitter: http://osms.it/twitter
Instagram for med: http://osms.it/instagram
Instagram for nursing: https://osms.it/ignursing
TikTok: https://osms.it/tiktok
Linkedin: https://osms.it/linkedin

Our Vision: Everyone who cares for someone will learn by Osmosis.
Our Mission: To empower the world’s clinicians and caregivers with the best learning experience possible. Learn more here: http://osms.it/mission

Medical disclaimer: Osmosis from Elsevier does not provide medical advice. Osmosis from Elsevier and the content available on the Osmosis from Elsevier properties (Osmosis.org, YouTube, and other channels) do not provide a diagnosis or other recommendation for treatment and are not a substitute for the professional judgment of a healthcare professional in diagnosis and treatment of any person or animal. The determination of the need for medical services and the types of healthcare to be provided to a patient are decisions that should be made only by a physician or other licensed healthcare provider. Always seek the advice of a physician or other qualified healthcare professional with any questions you have regarding a medical condition.

© 2024 Elsevier. All rights reserved.

In this video, Dr Mike explains the difference between obstructive and restrictive respiratory disorders. He shows the anatomical changes that occur and highlights how various lung volumes and capacities are changed. This highlights why pulmonary function tests (PFTs) are important.
Video Rating: / 5

Share this page:

Pathology, symptoms, causes, risk factors and treatments of COPD. This video is available for instant download licensing here: https://www.alilamedicalmedia.com/-/galleries/narrated-videos-by-topics/respiratory-diseases/-/medias/288d2bd4-256d-459e-b3cd-284a0b4b5b75-chronic-obstructive-pulmonary-disease-copd-narrated-animation
Voice by: Abbie Drum
©Alila Medical Media. All rights reserved.
Support us on Patreon and get FREE downloads and other great rewards: patreon.com/AlilaMedicalMedia
All images/videos by Alila Medical Media are for information purposes ONLY and are NOT intended to replace professional medical advice, diagnosis or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition.
Chronic obstructive pulmonary disease, or COPD, is a PROGRESSIVE inflammatory lung disease characterized by INCREASING breathing difficulty. Other symptoms include cough, most commonly with mucus, chest tightness and wheezing. COPD develops as a result of LONG-TERM exposure to irritants such as smoke, chemical fumes or dusts, and may go UNNOTICED for years. Most people show symptoms after the age of 40 when the disease is already in its advanced stage.
The lungs consist of millions of air tubes or airways, called bronchi and bronchioles, which bring air in and out of the body. These airways end with tiny air sacs – the alveoli – where the gas exchange process takes place. REPEATED inhalation of irritants results in a CHRONIC inflammatory response which brings in a large amount of defensive cells along with inflammatory chemicals from the immune system. Inflammation of the airways causes them to thicken and produce mucus, NARROWING the air passage – this is known as CHRONIC BRONCHITIS. Inflammatory chemicals also dissolve alveolar walls, resulting in DESTRUCTION of the air sacs – this is EMPHYSEMA. COPD is, basically, a COMBINATION of these two conditions.
Tobacco smoking is accountable for about 90% of COPD cases. These include current, former smokers and people frequently exposed to second-hand smoke.
Extended contact with harmful chemicals such as fumes from burning fuel or dusts, at home or workplace, may also cause COPD.
Genetics has been implicated in a small number of cases. Notably, a condition known as alpha-1 antitrypsin deficiency, or AAT deficiency, has been shown to increase risks for COPD and other lung diseases. AAT protein protects the lungs from damaging effects of enzymes released during inflammation. Low levels of AAT make lung tissues more vulnerable to destruction when inflamed. While people with AAT deficiency may develop COPD even WITHOUT smoking or exposure to harmful irritants, AAT deficient smokers are at MUCH greater risks.
COPD is diagnosed based on symptoms, history of exposure to irritants and lung function tests. The major test for COPD is SPIROMETRY, in which the patient is asked to blow into a tube connected to a machine – a spirometer. Spirometry evaluates pulmonary functions by measuring the volume and the speed of air flow during inhalation and exhalation.
There is no cure for COPD but treatments can relieve symptoms, prevent complications and slow down progression of the disease. The first and most essential step to treatment is to stop smoking and/or improve air quality at home and workplace. These are also the most effective measures in preventing the disease.
Other treatments include:
-Medication: bronchodilators are used to widen the airways; steroids to relieve inflammation.
-Vaccination against flu and pneumococcal pneumonia: this is to prevent serious complications COPD patients may have with these respiratory infections.
-Supplemental oxygen: this can improve quality of life provided that the patient no longer smokes.
-Breathing exercises and other therapies as part of a pulmonary rehabilitation program.
-Finally, surgery may be performed for severe cases when other methods fail. Surgical procedures include bullectomy, lung volume reduction surgery, where damaged parts of the lung are removed; and lung transplant, where the entire diseased lung is replaced with a healthy lung from a deceased donor.
Video Rating: / 5

Interstitial lung disease (ILD) causes scarring that damages lung tissue. Symptoms include shortness of breath, coughing and poor oxygen uptake.

For more information, visit https://uvahealth.com/services/pulmonary/interstitial-lung-disease

When someone is first diagnosed with interstitial lung disease or ILD, it’s actually an umbrella for a lot of different diseases, up to 200 of them. Depending on which type of ILD you have, your treatment can be very different. An example is in people who have idiopathic pulmonary fibrosis, or IPF. There are drugs that target the scaring process themselves, antifibrotic drugs that are available.

In contrast, people that have autoimmune conditions often respond to steroids or medications that suppress the immune system. These would be things that I wouldn’t use in an IPF patient but can be very useful in autoimmune conditions, or in conditions like sarcoidosis.

UVA has a really excellent interstitial lung disease program. It’s a big focus in our pulmonary division. The philosophy of the ILD clinic is to provide comprehensive, integrated care and develop a personalized treatment plan for each patient.
Video Rating: / 5

Share this page:

Dr. Rajesh S. Gokhale, Scientist at National Institute of Immunology and Co-founder of Vyome Biosciences challenges the notion of how chronic diseases should be looked upon and treated. An erudite insight into the cause and cure for such diseases, this talk is sure to give you a new direction as to how you view the medicine world around you. Dr. Gokhale is a scientist at NII and the co-founder of Vyome Biosciences (VYOME), a biopharmaceutical company developing drugs for dermatology care by utilizing genomics knowledge. He was the Director of CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB) for more than seven years. During his tenure, he established the IGIB South Delhi Campus and also led interdisciplinary initiatives in translational genomics research towards resolving complex diseases. Mr. Gokhale has done extensive research on the tuberculosis pathogen and on skin pigmentation homeostasis, with a particular interest in Vitiligo.
At TEDx JMI, his topic is “How can we cure chronic diseases” where Mr. Gokhale will reveal new ways to resolve recurring ailments which can reform the current the medical practice. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://www.ted.com/tedx

Share this page: